Overview
While CAR T-cell therapy (CAR T) has improved outcomes for patients across hematologic diseases, it also carries risk for adverse reactions that can increase healthcare resource utilization, such as hospitalizations and ICU stays. This research evaluates the real-world prevalence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving CAR T and assesses their associated healthcare burden, providing a comprehensive view of the challenges in managing these side effects.
Using the Flatiron Health Research Database, this study examines over 2,500 patients with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and multiple myeloma (MM) who received CAR T. Researchers found the prevalence of these CAR T associated toxicities were consistent with clinical trials. It was seen across disease cohorts that while the majority of the patients were treated in an inpatient setting and at academic centers, a meaningful proportion received therapy in outpatient or community settings, emphasizing increased diversity in care delivery.
Why this matters
Understanding the real-world side effects and resource utilization of CAR T helps in optimizing patient management and resource allocation. By providing insights into the healthcare burden, this study supports the development of strategies to mitigate side effects and improve patient care, ensuring the successful integration of CAR T into diverse clinical practices.